#Canada #Shareholders #Meeting #Quebec #Devonian Health

Devonian Health Group's Annual General and Special Meeting Results

On March 27, 2026, Devonian Health Group Inc., a biopharmaceutical company focused on innovative treatments for fibro-inflammatory diseases, hosted its Annual General and Special Meeting of Shareholders via an online format. This meeting was significant for several reasons, particularly the approval of various corporate governance proposals critical to the company’s future growth strategy.

Key Outcomes from the Meeting

During the meeting, shareholders participated in the decision-making process surrounding the election of the company's board members, the appointment of auditors, and an important amendment to the company's stock option plan.

Election of Directors

In a pivotal moment for Devonian, shareholders approved the appointment of several new directors, including Dr. André P. Boulet, who continues to serve as the Chairman and CEO. The newly elected members—Josh Muntner, Kira Sheinerman, and Luc Buisson—bring a wealth of experience and will be instrumental in refining the company's financial strategy.

• - Josh Muntner, a seasoned finance executive with over 25 years in the biotech sector, has a robust background in securing capital, highlighted by his leadership in raising over $9 billion through various financings. He holds an MBA from the UCLA Anderson School of Management.

• - Dr. Kira Sheinerman, with her background as a Managing Director of Investment Banking at H.C. Wainwright, offers deep expertise in fundraising and strategic advisory services. Her strong academic credentials include a PhD in Biomedical Sciences and an MBA.

• - Luc Buisson is recognized for his strategic insights, obtained from a career spanning over 35 years in global investment banking, including significant roles advising corporations and governments on vast financial transactions.

Dr. Boulet expressed satisfaction with the new appointments, stressing their experience's potential to enhance Devonian's growth and deliver substantial value to shareholders.

Appointment of Auditors

As part of ensuring robust financial oversight, the shareholders appointed MNP LLP as the independent auditor for the fiscal year ending July 31, 2026. This appointment reflects the company's commitment to transparency and financial integrity. The remuneration for MNP LLP will be determined by the board of directors.

Amendment to Stock Option Plan

An amendment to the company's stock option plan was approved, allowing an increase in the number of shares reserved for issuance. This adjustment was necessary for the company's growth strategy, demonstrating the Board's proactive approach to retaining talent and fostering an environment for innovation. The stock option plan aims to align participant interests with shareholder value creation and is now set to represent 20% of the outstanding shares.

Devonian's Outlook

Devonian Health Group, founded in 2015 and headquartered in Quebec, aims to address unmet medical needs through the development of therapies for autoimmune fibro-inflammatory diseases. The company is steadfast in its mission to enhance quality of life through innovative healthcare solutions. With a strong pipeline and a focus on high-value cosmeceuticals, Devonian is poised for future success in both the biopharmaceutical and healthcare markets.

Conclusion

The outcomes from the Annual General and Special Meeting underscore Devonian Health Group’s commitment to strategic growth and shareholder engagement. The addition of seasoned professionals to the board is expected to yield valuable insights that will support the company's vision of becoming a leader in its field. Shareholders and stakeholders can look forward to future developments as Devonian continues its journey toward innovation and excellence in healthcare.

For more information, visit Devonian's website.